Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anixa Biosciences, Inc. filings document regulatory disclosures for a cancer-focused biotechnology company developing vaccine and CAR-T therapy programs. Recent Form 8-K reports include Regulation FD disclosures on the company's ovarian cancer CAR-T program, lira-cel, and its investigational breast cancer vaccine, including related press releases and scientific-presentation exhibits.
The company's proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, common-stock voting results, and other governance matters. These filings provide the formal record for Anixa's public-company reporting around clinical-program updates, stockholder actions, and corporate oversight.
Anixa Biosciences director Lewis H. Titterton Jr. filed a Form 4 reporting a grant of employee stock options. On January 5, 2026, he received options to purchase 25,000 shares of Anixa Biosciences common stock at an exercise price of $3.18 per share under the company’s 2018 Share Incentive Plan.
The options vest and become exercisable in twelve equal monthly installments beginning January 31, 2026, and are scheduled to expire on January 5, 2036. Following this grant, Titterton directly holds 25,000 derivative securities (stock options) related to Anixa common stock.
Anixa Biosciences Inc executive Michael J. Catelani, who serves as President, COO and CFO, reported a new stock option grant. On January 5, 2026, he received an employee stock option giving him the right to buy 175,000 shares of Anixa common stock at an exercise price of $3.18 per share under the company’s 2018 Share Incentive Plan. The filing states that these options were granted at no cost to him as a derivative security and are held directly.
The options vest in thirty-six equal monthly installments beginning on January 31, 2026, meaning portions of the grant become exercisable each month over a three-year period. After this grant, Catelani beneficially owns 175,000 stock options, all reported as directly owned.
Anixa Biosciences director Arnold M. Baskies received a grant of employee stock options for 25,000 shares of common stock on January 5, 2026. The options have an exercise price of $3.18 per share and were granted as a Right-To-Buy under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. They vest in twelve equal monthly installments beginning January 31, 2026 and expire on January 5, 2036. Following this award, Baskies holds 25,000 derivative securities directly in the form of these options, which had no purchase price at grant.
Anixa Biosciences Inc director Lewis H. Titterton, Jr. reported an insider stock transaction. On 12/15/2025, he exercised an employee stock option granted on 02/18/2016 with an exercise price of $2.92 per share, acquiring 16,000 shares of Anixa Biosciences common stock through a transaction coded "M" (option exercise).
Following this transaction, Titterton directly beneficially owned 969,334 shares of Anixa Biosciences common stock. The option covered 16,000 underlying shares, and after the exercise the number of derivative securities reported for this option position was 0.
Anixa Biosciences, Inc. reported that it and The Cleveland Clinic Foundation presented final data from a Phase 1 clinical trial of Anixa’s investigational breast cancer vaccine. The data were shared in a presentation by Justin Johnson, Ph.D., a program manager at Cleveland Clinic and co-inventor of the vaccine technology, and were followed by a company press release. The 8-K primarily alerts investors to the completion and public disclosure of this early-stage clinical trial dataset, with additional details contained in the attached press release and presentation exhibits.
Anixa Biosciences (ANIX) CEO Amit Kumar reported an insider option exercise. On 10/30/2025, he exercised 200,000 stock options at $2.92 per share (code M), adding common shares.
To cover the exercise price and tax withholding, 169,439 shares were withheld and reported as a disposition at $4.06 (code F). Following these transactions, Kumar beneficially owns 610,486 shares directly. The filing notes no open-market share sales in connection with this exercise.
Anixa Biosciences, Inc. (ANIX) filed a shelf registration on Form S-3 that outlines the types of securities it may offer, exhibits that will be incorporated, and selected financial and offering metrics. The prospectus lists potential securities including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares and units. It incorporates multiple recent SEC reports including the annual report for the year ended October 31, 2024 and quarterly reports through the quarter ended July 31, 2025. The document shows a net tangible book value per share of $0.46 as of July 31, 2025, an increase per share attributable to new investors of $1.23, and a dilution per share to new investors of $1.29. Estimated offering expenses list legal fees of $65,000, accounting fees of $15,000, and a total estimated cost of $96,146. The exhibits index identifies underwriting agreements, forms of securities, legal opinions, and the calculation of filing fees among the attached documents.
Anixa Biosciences (ANIX) reported continued operating losses but states it has sufficient liquidity for over 12 months. The company recorded net losses of $2.3 million for the three months and $8.3 million for the nine months ended July 31, 2025, with losses from operations of $2.4 million and $8.8 million, respectively. Cash, cash equivalents and short-term investments totaled $16,029,000 at July 31, 2025, down from approximately $19,924,000 at October 31, 2024, a reduction of about $3.9 million for the nine months. During the period the company raised approximately $1.924 million, net, from an at-the-market equity offering of 611,686 shares and issued options under its 2018 Share Incentive Plan (1,430,000 granted during the nine months). Stock-based compensation was $829,000 and $2,822,000 for the three- and nine-month periods, respectively. The company continues a 2,000 sq. ft. operating lease for its San Jose office with base rent of approximately $5,000 per month.
Form 4 filing for Anixa Biosciences (ANIX): Company director Lewis H. Titterton, Jr. bought 10,000 common shares on 07/31/2025 at $3.08 per share, an outlay of roughly $30.8 k.
The purchase lifts his direct holding to 953,334 shares. No sales or derivative transactions were disclosed. Because directors are presumed to possess intimate knowledge of corporate prospects, open-market buying is generally interpreted as a positive signal of confidence rather than a routine option exercise.